Focus: Paradromics is a brain-computer interface (BCI) biotech company headquartered in Austin, TX, developing the Connexus platform for neurodegenerative diseases like ALS. The company is early-stage with a single active clinical trial and recent FDA clearance for expanded device compatibility.
Profile data last refreshed 9h ago · AI intelligence enriched 3w ago
Growing — net +5 jobs in 30d
6 jobs added vs 1 removed. Steady team buildout.
Paradromics offers high-risk, high-reward opportunity for engineers and technical professionals seeking to build next-generation neurotech, but limited operational scale and disclosed financial health require strong conviction on the team and platform.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Paradromics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Paradromics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Paradromics gets FDA nod to expand brain implant study recruitment - MobiHealthNews
Paradromics gets FDA nod to expand brain implant study recruitment MobiHealthNews
Paradromics gets FDA nod for broader BCI device compatibility - Medical Device Network
Paradromics gets FDA nod for broader BCI device compatibility Medical Device Network
FDA expands device compatibility for Paradromics' brain-computer interface - Medical Economics
FDA expands device compatibility for Paradromics' brain-computer interface Medical Economics
Paradromics Gets FDA Approval To Embed BCI Software In Personal Devices - Medtech Insight
Paradromics Gets FDA Approval To Embed BCI Software In Personal Devices Medtech Insight
Paradromics names William J. Marks Jr. as CCO - medicalbuyer.co.in
Paradromics names William J. Marks Jr. as CCO medicalbuyer.co.in
I implanted Paradromics' first long-term brain chip in a patient. I began my career as an electrical engineer. - AOL.com
I implanted Paradromics' first long-term brain chip in a patient. I began my career as an electrical engineer. AOL.com
Showing 6 of 8 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo